Review: Bupropion and SSRI-induced side effects
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Selective serotonin reuptake inhibitors (SSRIs) are a first line treatment option for millions of patients, due to the positive balance between efficacy and tolerability. However, some side effects associated with their use, can impair quality of life and compliance with treatment. This paper reviews the prevalence of sexual dysfunction, weight gain and emotional detachment during SSRI treatment, the profile of bupropion for each of these events and the ability of bupropion to reverse them. Double-blind trials, open-label trials and anecdotical reports derived from Medline were included. First, there is robust evidence that SSRIs can induce sexual side effects and that bupropion causes less sexual dysfunction than SSRIs. There is limited, mainly open-label evidence that bupropion can reverse SSRI-induced sexual side effects. Second, there is good evidence that long-term treatment with some SSRIs can result in weight gain and that long-term treatment with bupropion can result in a small weight loss. There is only anecdotical evidence that bupropion can reverse SSRI-induced weight gain. Third, treatment with SSRIs has been associated with `emotional detachment', although controversy exists about this concept. No data are available on the profile of bupropion for `emotional detachment' or for the reversal of SSRI-induced `emotional detachment' by bupropion-addition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence of Sexual Dysfunction Among Newer Antidepressants
Clayton, A. H., Pradko, J. F., Croft, H. A., Montano, C. B., Leadbetter, R. A., Bolden-Watson, C., Bass, K. I., Donahue, R. M. J., Jamerson, B. D., & Metz, A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0414 · Cited by 542
Montejo-gonzàlez, A. L., Llorca, G., Izquierdo, J. A., Ledesma, A., Bousono, M., Calcedo, A., Carrasco, J. L., Ciudad, J., Daniel, E., De LA Gandara, J., et al. (1997) · Journal of Sex & Marital Therapy · doi:10.1080/00926239708403923 · Cited by 505 · cited 1×
“Most authors agree that serotonergic drugs can affect all phases of the sexual response cycle (Montejo-Gonzalez et al., 1997; Segraves, 1998; Rosen et al., 1999; Montejo et al., 2001; Fava and Rankin, 2002; Balon, 2006).”
BackgroundStahl, S. M., Pradko, J., Haight, B. R., Modell, J. G., Rockett, C. B., & Learned-Coughlin, S. (2004) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v06n0403 · Cited by 495
Continuity of antidepressant treatment for adults with depression in the United States
Olfson, M., Marcus, S. C., Tedeschi, M., & Wan, G. J. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.101 · Cited by 392 · cited 1×
“Unfortunately, 32–60% of patients discontinue their pharmacotherapy in the first three months, often without informing their physician (Myers and Branthwaite, 1992; Simon et al., 1993; Maddox, 1994; Demyttenaere et al., 2001; Olfson et al., 2006).”
BackgroundAntidepressant-Induced Sexual Dysfunction
Gregorian, R. S., Golden, K. A., Bahce, A., Goodman, C., Kwong, W. J., & Khan, Z. M. (2002) · Annals of Pharmacotherapy · doi:10.1345/aph.1a195 · Cited by 320 · cited 1×
“Several methodological issues complicate the search for a reliable prevalence-estimate, and make it difficult to compare the numerous reports in the field (Baldwin, 2001; Gregorian et al., 2002; Montgomery et al., 2002; Balon, 2006).”
ResultBupropion SR Enhances Weight Loss: A 48‐Week Double‐Blind, Placebo‐ Controlled Trial
Anderson, J. W., Greenway, F. L., Fujioka, K., Gadde, K. M., McKenney, J., & O'Neil, P. M. (2002) · Obesity Research · doi:10.1038/oby.2002.86 · Cited by 315 · cited 1×
“A more extended placebo-controlled, double-blind study was conducted by Anderson et al. (2002).”
BackgroundMasand, P., & Gupta, S. (2002) · Annals of Clinical Psychiatry · doi:10.3109/10401230209147454 · Cited by 311
Hu, X. H., Bull, S. A., Hunkeler, E. M., Ming, E., Lee, J. Y., Fireman, B., & Markson, L. E. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0712 · Cited by 235
Fava, M., Graves, L. M., Benazzi, F., Scalia, M. J., Iosifescu, D. V., Alpert, J. E., & Papakostas, G. I. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1113 · Cited by 229
Bupropion SR vs. Placebo for Weight Loss in Obese Patients with Depressive Symptoms
Jain, A. K., Kaplan, R. A., Gadde, K. M., Wadden, T. A., Allison, D. B., Brewer, E. R., Leadbetter, R. A., Richard, N., Haight, B., Jamerson, B. D., et al. (2002) · Obesity Research · doi:10.1038/oby.2002.142 · Cited by 205
Antidepressant medications: a review of the evidence for drug-induced sexual dysfunction
Montgomery, S. (2002) · Journal of Affective Disorders · doi:10.1016/s0165-0327(01)00313-5 · Cited by 205
Apathy and Indifference in Patients on Fluvoxamine: and Fluoxetine
HOEHN-SARIC, R., LIPSEY, J. R., & McLEOD, D. R. (1990) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199010000-00007 · Cited by 156
Bupropion Sustained Release Versus Paroxetine for the Treatment of Depression in the Elderly
Weihs, K. L., Settle, E. C., Batey, S. R., Houser, T. L., Donahue, R. M. J., & Ascher, J. A. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n0309 · Cited by 150
The compliance with antidepressants in general practice
Maddox, J. C., Levi, M., & Thompson, C. (1994) · Journal of Psychopharmacology · doi:10.1177/026988119400800108 · Cited by 148
Opbroek, A., Delgado, P. L., Laukes, C., McGahuey, C., Katsanis, J., Moreno, F. A., & Manber, R. (2002) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145702002870 · Cited by 147
The Pharmacologic Management of SSRI-Induced Side Effects: A Survey of Psychiatrists
Dording, C., Mischoulon, D., Petersen, T., Kornbluh, R., Gordon, J., Nierenberg, A., Rosenbaum, J., & Fava, M. (2002) · Annals of Clinical Psychiatry · doi:10.3109/10401230209147450 · Cited by 109
A Double-Blind Comparison of Fluvoxamine and Paroxetine in the Treatment of Depressed Outpatients
Kiev, A., & Feiger, A. (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n0402 · Cited by 89
Garland, E. J., & Baerg, E. A. (2001) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/104454601750284090 · Cited by 80
Maina, G., Albert, U., Salvi, V., & Bogetto, F. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n1011 · Cited by 79 · cited 1×
“The proportion of patients with a 7% weight increase was 4.5 and 8.7% for sertraline and fluoxetine respectively, 14.3, 10.7 and 14.3% for citalopram, fluvoxamine and paroxetine respectively and 34.8% for clomipramine (Maina et al., 2004).”
BackgroundInfluentialBolling, M. Y., & Kohlenberg, R. J. (2004) · Psychotherapy and Psychosomatics · doi:10.1159/000080392 · Cited by 74
Weihs, K. L., Houser, T. L., Batey, S. R., Ascher, J. A., Bolden-Watson, C., Donahue, R. M. J., & Metz, A. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01317-8 · Cited by 65
Bupropion Treatment of Olanzapine-Associated Weight Gain: An Open-Label, Prospective Trial
Gadde, K. M., Zhang, W., & Foust, M. S. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000227354.54074.5d · Cited by 24 · cited 1×
“The authors found that participants who received bupropion SR scored significantly better on sexual arousal, orgasm completion and sexual satisfaction, but only numerically better on desire scores (Segraves et al., 2004). In healthy men, no differences were found in self-reported sexual function, number of nocturnal e…”
Background
Cited by
Treating comorbid anxiety and depression: psychosocial and pharmacological approaches
Coplan, J. D. (2015) · World Journal of Psychiatry · doi:10.5498/wjp.v5.i4.366 · Cited by 207
Drug safety evaluation of naltrexone/bupropion for the treatment of obesity
Verpeut, J. L., & Bello, N. T. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.909405 · Cited by 202
“Based on its low affinity for the 5HT transporter, it is not associated with sexual dysfunction or weight gain, which is typically observed with some selective serotonin reuptake inhibitors (SSRIs), thus bupropion is considered an atypical antidepressant [57-59].”
BackgroundMontejo, A. L., Montejo, L., & Baldwin, D. S. (2018) · World Psychiatry · doi:10.1002/wps.20509 · Cited by 189
Shen, J., Li, Y., Qu, C., Xu, L., Sun, H., & Zhang, J. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.01.031 · Cited by 127
Belleville, G. (2010) · The Canadian Journal of Psychiatry · doi:10.1177/070674371005500904 · Cited by 100
Metadata
- Authors
- Demyttenaere, K., & Jaspers, L.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2008-09
- Volume
- 22
- Issue
- 7
- Pages
- 792-804
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W1999086370
- Cited by
- 132
- References
- 22
- FWCI
- 8.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.